Abstract
Objective We compared the clinical characteristics, findings and outcomes of hospitalized patients with coronavirus disease 2019 (COVID-19) or influenza to detect relevant differences. Methods From December 2019 to April 2020, we recruited all eligible hospitalized adults with respiratory infection to a prospective observational study at the HUS Jorvi Hospital, Finland. Influenza and SARS-CoV-2 infections were confirmed by RT-PCR. Follow-up lasted for at least 30 days from admission. Results We included 61 patients, of whom 28 were COVID-19 and 33 influenza patients with median ages of 53 and 56 years. Majority of both COVID-19 and influenza patients were men (61% vs 67%) and had at least one comorbidity (68% vs 85%). Pulmonary diseases and current smoking were less common among COVID-19 than influenza patients (5 [18%] vs 15 [45%], P=0.03 and 1 [4%] vs 10 [30%], P=0.008). In chest x-ray at admission, ground-glass opacities and consolidations were more frequent among COVID-19 than influenza patients (19 [68%] and 7 [21%], P < 0.001). Severe disease and intensive care unit (ICU) admission occurred more often among COVID-19 than influenza patients (26 [93%] vs 19 [58%], P=0.003 and 8 [29%] vs 2 [6%], P=0.034). COVID-19 patients were hospitalized longer than influenza patients (6 days [IQR 4-21] vs 3 [2-4], P<0.001). Conclusion Bilateral ground-glass opacities and consolidations in chest X-ray may help to differentiate COVID-19 from influenza. Hospitalized COVID-19 patients had more severe disease, required longer hospitalization and were admitted to ICU more often than influenza patients, which has important implications for public health policies.
Competing Interest Statement
Raija Auvinen, Kirsi Skogberg, Hanna Nohynek, Ritva Syrjänen and Niina Ikonen report an institutional grant to HUS and THL from the DRIVE project funded by IMI under grant agreement No 777363 during the conduct of the study. Currently, Raija Auvinen is working at THL as a part-time safety physician of a clinical trial on influenza vaccine effectiveness (FinFluHD study), for which THL has received research support from Sanofi Pasteur Inc. FinFluHD study is not related to the current study. Hanna Nohynek is an investigator at THL and coordinates the THL DRIVE project which has received funding from Innovative Medicines Initiative. Ritva Syrjänen is a co-investigator in pneumococcal studies for which THL has received research support from GlaxoSmithKline Biologicals. Currently Ritva Syrjänen is a co-investigator in the FinFluHD study for which THL has received research support from Sanofi Pasteur Inc. Neither of these studies is related to the current study. Other authors declare no competing interests.
Funding Statement
This study was funded by the DRIVE Project, which receives funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking under grant agreement No 777363. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation and EFPIA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was granted by the Local Ethics Committee of the Helsinki University Hospital (Date 3 October 2019, case number: HUS/2517/2018)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data are available from the corresponding author upon reasonable request respecting GDPR and with permission from HUS and THL.
